Treatment of Priapism with Automated Red Cell Exchange and Hyperbaric Oxygen in an 11-year-old Patient with Sickle Cell Disease

Orak Hücre Hastalığı olan 11 Yaşında Bir Çocukta Gelişen Priapizmin Otomatik Eritrosit Değişimi ve Hiperbarik Oksijen ile Tedavisi

Abstract

Priapism affects up to 50% of all males with sickle cell disease, and there is no standard treatment. Delayed and unsuccessful treatment leads to corporal fibrosis and impotence. It is therefore necessary to determine the best treatment methods for this complication in order to offer effective interventions to all affected patients. Herein we report an 11-year-old patient with sickle cell disease that presented with priapism 72 h after onset, and was successfully treated with automated red cell exchange and hyperbaric oxygen following unsuccessful surgical and conventional interventions.

Key Words: Treatment of priapism, Automated red cell exchange, Hyperbaric oxygen therapy, Sickle cell disease

Introduction

Priapism is the persistence of an erection in the absence of sexual desire that fails to subside despite orgasm. There are 2 types of priapism: low-flow ischemic (veno-occlusive priapism), which is the form seen in sickle cell disease (SCD), and high-flow priapism (non-ischemic), which is associated with external trauma that damages the cavernosal artery. Sickle cell disease is one of the most common underlying diseases responsible from venous occlusion in low-flow ischemic priapism [1,2]. Priapism occurs in 30%-89% of males with SCD [3-5]. The prevalence of priapism in children with SCD was estimated to be 2%-6%...
hyperbaric chamber at 2.5 ATA and 45 ft H₂O did not occur. The patient was taken into a large, walk-in shunt. Despite the surgical intervention, detumescence was achieved. Performing a corpora cavernosa-glans penis shunt was performed immediately in addition to hyperbaric oxygen following unsuccessful surgical and conventional interventions.

**Case Report**

An 11-year-old boy with SCD presented to the emergency department with a painful and persistent erection. Initial investigations confirmed sickle cell abnormality (92% SS homozygous), based on hemoglobin electrophoresis, and showed severe anemia (Hb: 5.7 g dL⁻¹). The patient was treated with hydration, sedation, oxygenation, and transfusion of packed red blood cells. The machine was primed with cross-matched compatible red blood cells. This achieved an Hb level of 10.6 g dL⁻¹ with an Hb S fraction of 7.7%. There were no procedural complications. Upon examination after the first erythrocyte apheresis, improvement in the degree of erection and pain was evident, and priapism almost completely resolved after the second apheresis treatment. Hyperbaric oxygen treatment were applied 11 sessions. The patient’s priapism continued for 6 d before detumescence was complete. We did not observe any complications related to hyperbaric oxygen treatment in our patient. During a 4-year follow up period priapism did not reoccur.

**Discussion**

It is thought that priapism is caused by sickle cells occluding the venous outflow of blood from the corpora of the penis. Episodes most commonly start during sleep or upon awakening, last about 2 h, and first occur during adolescence and pre-puberty. Some episodes resolve spontaneously within 2-3 h. Prolonged episodes can cause irreversible ischemic injury and lead to impotence. Symptoms of priapism are classified as acute (lasting >3 h), recurrent or stuttering (lasting ≤3 h and resolving spontaneously), and chronic, which is a rare condition in which the penis is persistently semi-erect, but not painful. Priapism is usually accompanied by pain and tenderness.

The presented patient was an 11-year-old boy with SCD. Priapism can occur in all age groups, with reported peak incidences in SCD patients between the ages of 5 and 10 years, and 20 and 50 years. Treatment for acute attacks includes hydration, sedation, oxygenation, aspiration, and irrigation with an α-adrenergic agonist and exchange transfusion; these interventions may be helpful within the initial 10-12 h of onset. Surgical treatments for priapism are designed to remove blood from the corpora cavernosa. Early intervention with corporal aspiration and irrigation with adrenergic agonists was recently reported to be successful in an outpatient clinic. Prior to presentation to our hospital, the presented patient underwent corporal aspiration that was unsuccessful, and the initial therapies; hydration, sedation, oxygenation was not applied.

At presentation to our hospital (72 h after the onset of symptoms) it was too late for conventional treatment approaches in the presented case. A corpora cavernosa-glans penis shunt was performed immediately in addition to conventional management with hydration, sedation, and oxygenation, but the symptoms were not relieved. As reported, the success of surgical treatment is associated...
with its timing (<48 h of the onset of symptoms). Patients suffer physically and most progress to impotency, in part because of delayed treatment [15,16]. The precise mechanism of priapism in patients with SCD remains unclear. It is assumed that a normal erection decreases oxygen tension in the corpora cavernosa, predisposing to erythrocyte sickling [17]. With regard to pathophysiology, hyperbaric oxygen treatment has been successfully used for SCD complications, especially retinopathy, hyphema, and painful crisis [18-21]. To the best of our knowledge the literature does not contain any data on hyperbaric oxygen treatment for priapism in SCD patients.

In consideration of the presented patient’s serious condition, we initiated hyperbaric oxygen treatment. During this period automated red cell exchange was performed for 2 d and Hb S decreased to 7.7% from 92%, which is a desired level. The benefit of red cell exchange transfusion in SCD patients with priapism remains unclear [22]. McCarthy et al. reported that automated red cell exchange is not useful when initiated ≥1 d after the onset of priapism and when conservative management fails [8]. In contrast, we successfully performed automated red cell exchange 4 d after the onset of priapism, even though previous surgical and conventional treatments failed. Although hyperbaric oxygen appears to have no effect on the morphology of sickle cells in vitro [23], we think it was beneficial in the presented patient.

Hyperbaric oxygen therapy can result in arterial oxygen tension in the range of 1000-1600 mmHg and tissue oxygen tension close to 400 mmHg. Several indications for the use of hyperbaric oxygen therapy have been described [24], including carbon monoxide poisoning, necrotizing soft tissue infection, decompression sickness, and arterial gas embolism. On the other hand, there are some complications and side effects related to hyperbaric oxygen therapy [25]; pressure equalization problems in the middle ear, sinus squeeze, and tooth squeeze are common complications associated with hyperbaric oxygen therapy. No randomized or controlled studies on the complications of hyperbaric oxygen therapy in pediatric patients have been reported, but a few case reports have been reported. The complications associated with hyperbaric oxygen therapy are strongly correlated with the number of treatments. Ambirou et al. reported a complication rate of 8.1% in patients that received 11-29 treatments, and that when the number of hyperbaric oxygen treatments was ≥30 the complication rate was 17.1% [26]. In the presented patient hyperbaric oxygen treatment was completed after 11 sessions, without any complications. Despite the use of combination treatments, low-flow priapism may result in impotence or erectile dysfunction secondary to corporeal fibrosis [15]. In conclusion, the results obtained in the present case suggest that automated red cell exchange and hyperbaric oxygen may be a good combination for the treatment of resistant priapism in SCD patients.

Conflict of interest statement

The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

1. Muthall JP, Honig SC. Priapism: Etiology and Management. Acad Emerg Med 1996; 3: 810-816
2. Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. In: Walsh PC, Retik AB, Darracott Vaughan E Jr, Wein AJ editor(s). Campbell’s Urology. 7th Edition. Vol. 2, Philadelphia: W.B. Saunders, 1998: 1155–1180
3. Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med 1980; 140: 1434-1437
4. Fowler JE Jr, Koshy M, Strub M, Chinn SK. Priapism associated with the sickle cell hemoglobinopathies: Prevalence, natural history and sequelae. J Urol 1991; 145: 65-68
5. Mandatakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. J Ped Hematol Oncol 1999; 21: 518-522
6. Hasen HB, Raines SL. Priapism associated with sickle cell disease. J Urol 1962; 88: 71-76
7. Tarry WF, Duckett JW, Synder HM 3rd. Urological complications of sickle cell disease in pediatric population. J Urol 1987; 138: 592-594
8. McCarthy Lj, Vattuone J, Weidner J, Skipworth E, Fernandez C, Jackson L, Rothenberger S, Waxman D, Miraglia C, Porcu P, Danielson CF. Do Automated Red Cell Exchanges Relieve Priapism In Patients with Sickle Cell Anemia? Ther Apher 2000; 4: 256-258
9. Powars DR, Johnson CS. Priapism. Hematol Oncol Clin North Am 1996; 10: 1363-1372
10. Serjeant GR, Serjeant BE. Sickle cell disease. 3rd edition. New York: Oxford University Press; 2001
11. Hamre MR, Harmon EP, Kirkpatrick DV, Stern MJ, Humbert JR. Priapism as a complication of sickle cell disease. J Urol 1991; 145: 1-5
12. Serjeant GR, De Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sickle cell disease. Lancet 1985; 2: 1274-1276
13. Dewan PA, Tan HL, Auldist AW, Moss DI. Priapism in childhood. Br J Urol 1989; 64: 541-545
14. Adeoyeju AB, Olujohungbe AB, Morris J, Yardumian A, Bareford D, Akenova A, Akinyanju O, Cinkotai K, O'Reilly PH. Priapism in sickle-cell disease; incidence, risk factors and complications—an international multicentre study. BJU Int 2002; 90: 898–902
15. Chakrabarty A, Upadhay J, Dhabuwala CB, Sarnaik S, Perlmutter AD, Connor JP. Priapism associated with sickle cell hemoglobinopathy in children: Long-term effects on potency. J Urol 1996; 155: 1419–1423
16. Maples BL, Hagemann TM. Treatment of priapism in pediatric patients with sickle cell disease. Am J Health Syst Pharm 2004; 61: 355–363
17. Francis RB, Johnson CS. Vascular occlusion in sickle cell disease. Current concepts and unanswered questions. Blood 1991; 77: 1405–1414
18. Wallyn CR, Jampol LM, Goldberg MF, Zanetti CL. The use of hyperbaric oxygen therapy in the treatment of sickle cell hyphema. Invest Ophthalmol Vis Sci 1985; 26: 1155-1158
19. Freilich DB, Seelenfreund MH. Further studies in the use of hyperbaric oxygen in retinal detachment with sickle cell anemia. Mod Probl Ophthalmol 1975; 15: 313-317
20. Freilich DB, Seelenfreund MH. Long-term follow-up of scleral buckling procedures with sickle cell disease and retinal detachment treated with the use of hyperbaric oxygen. Mod Probl Ophthalmol 1977; 18: 368-372
21. Reynolds JD. Painful sickle cell crisis. Successful treatment with hyperbaric oxygen therapy. JAMA 1971; 216 (12): 1977-1978
22. Danielson CF. The Role of Red Blood Cell Exchange Transfusion in the Treatment and Prevention of Complications of Sickle Cell Disease. Ther Apher 2002; 6: 24-31
23. Mychaskiw G 2nd, Woodyard SA, Brunson CD, May WS, Eichhorn JH. In vitro effects of hyperbaric oxygen on sickle cell morphology. J Clin Anesth 2001; 13: 255-258
24. Moon RE, Feldmeier JJ. Hyperbaric oxygen: An evidence based approach to its application. Undersea Hyperb Med 2002; 29: 1-3
25. Jain KK. Indications, contraindications, and complications of HBO therapy. In: Jain KK, editor. Textbook of hyperbaric medicine. 4th revised and expanded edition. Cambridge: Hogrefe & Huber Publishers 2004: 73-78
26. Ambiru S, Furuyama N, Aono M, Otsuka H, Suzuki T, Miyazaki M. Analysis of risk factors associated with complications of hyperbaric oxygen therapy. J Crit Care 2008; 23: 295-300